关键信息
-
基因名
HLA-A*11:01&B2M&KRAS G12C(VVVGACGVGK) Monomer
- 应用
-
别名
MHC; KRAS; K-Ras 2; KRAS2; C-K-RAS; CFC2; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KRAS1; KRAS2; NS; NS3; RASK2; GTPase Kras; KI-RAS; RALD
-
种属
Human
-
表达系统
HEK293
-
标签
C-Avi;C-8*His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
AAV53343.1 (G25-T305)&P61769
-
表达区间
AAV53343.1 (G25-T305)&P61769 (I21-M119)&VVVGACGVGK
-
分子量
53-63 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
质检流程
相关产品
背景信息
HLA-A*11:01, a specific variant of the human leukocyte antigen (HLA) class I, plays a pivotal role in immune response by presenting peptides to T cells. The study of HLA-A*11:01 monomers is crucial for understanding peptide-HLA interactions and their implications in immune recognition, particularly in the context of cancer immunology. The inclusion of B2M (beta-2 microglobulin) is essential for the proper folding and stability of the HLA-A*11:01 molecule, as it forms a part of the HLA class I complex. KRAS, a well-known oncogene, often harbors mutations that lead to aberrant signaling pathways and cancer progression. Specifically, the G12C mutation in KRAS is associated with various malignancies, including lung and colorectal cancers. The peptide VVVGACGVGK derived from the KRAS G12C mutation can be presented by HLA-A*11:01, making it a promising target for therapeutic vaccination strategies. Research on the HLA-A*11:01 & B2M & KRAS G12C monomer recombinant protein aims to elucidate the structural and functional relationships between these components. This understanding is vital for the development of novel immunotherapies that target cancer by harnessing the body’s immune system to recognize and eliminate tumor cells presenting mutated KRAS peptides. Ultimately, this research could lead to improved clinical outcomes for patients with KRAS-driven tumors by facilitating the design of personalized vaccines that induce robust T cell responses against cancer cells.
